Espindolol 是一种新型非选择性 β 受体阻滞剂，具有中枢 5-HT1a 和部分 β2 受体激动剂作用。

Espindolol is a novel non-selective β blocker with central 5-HT1a and partial β2 receptor agonist effects.

Placebo-treated rats progressively lost body weight (-15.5 ± 7.2 g), lean mass (-1.5 ± 4.2 g), and fat mass (-15.6 ± 2.7 g), while espindolol treatment increased body weight (+8.0 ± 6.1 g, p< 0.05), particularly lean mass (+43.4 ± 3.5 g, p< 0.001), and reduced fat mass further (-38.6 ± 3.4 g, p< 0.001). Anabolic/catabolic signaling was assessed in gastrocnemius muscle. Espindolol decreased proteasome and caspase-3 proteolytic activities by approximately 50 % (all p< 0.05)[1].

26328-11-0

C14H20N2O2

248.32

AGI001;MT 102;AGI-001;AGI 001;MT-102;S-吲哚洛尔;MT102

DMSO:55 mg/ml (221.49 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years